Survival outcomes of patients treated with BsAbs after CART. (A) Patients with elevated LDH had inferior mPFS compared to those without elevated LDH (mPFS = NR vs 85 days; 95% CI, 46-124; P = .01). There was no difference in mOS based on elevation in LDH (mOS = NR vs 177 days; 95% CI, 131-223; P = .13). (B) Patients with PRD had inferior mPFS and mOS compared to patients who did not have PRD (mPFS, 184 days [95% CI, 71-297] vs 85 days [95% CI, 8-162]; P = .05; mOS, 532 days [95% CI 0.0-1199] vs 161 days [95% CI 71- 251]; P = .05). (C) Presence of DHL correlated with inferior mPFS and mOS compared to without DHL (mPFS, 168 days [95% CI, 126-210] vs 80 days [95% CI, 22-138]; P = .06; mOS, 654 days [95% CI, 72-1236] vs 115 days [95% CI, 68-162]; P = .01). (D) Patients who received CD20 × CD3 BsAbs as first-line salvage after CART had improved mPFS compared to patients who received BsAbs as a later line of therapy (148 days [95% CI, 51-245] vs 103 days [95% CI, 45-161]; P = .07), but there was no difference in mOS (NR vs 187 days [95% CI, 139-235]; P = .24). CI, confidence interval; NR, not reached; WNL, within normal limits.